12 reports of this reaction
1.7% of all TOLNAFTATE 1% reports
#10 most reported adverse reaction
BRONCHOPULMONARY ASPERGILLOSIS is the #10 most commonly reported adverse reaction for TOLNAFTATE 1%, manufactured by Meijer Distribution Inc. There are 12 FDA adverse event reports linking TOLNAFTATE 1% to BRONCHOPULMONARY ASPERGILLOSIS. This represents approximately 1.7% of all 724 adverse event reports for this drug.
Patients taking TOLNAFTATE 1% who experience bronchopulmonary aspergillosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRONCHOPULMONARY ASPERGILLOSIS is a less commonly reported adverse event for TOLNAFTATE 1%, but still significant enough to appear in the safety profile.
In addition to bronchopulmonary aspergillosis, the following adverse reactions have been reported for TOLNAFTATE 1%:
The following drugs have also been linked to bronchopulmonary aspergillosis in FDA adverse event reports:
BRONCHOPULMONARY ASPERGILLOSIS has been reported as an adverse event in 12 FDA reports for TOLNAFTATE 1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRONCHOPULMONARY ASPERGILLOSIS accounts for approximately 1.7% of all adverse event reports for TOLNAFTATE 1%, making it a notable side effect.
If you experience bronchopulmonary aspergillosis while taking TOLNAFTATE 1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.